Bifunctional Compounds for Pulmonary Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary disorders like asthma and COPD rely on separate β2 adrenergic receptor agonists and muscarinic receptor antagonists, which are cumbersome to formulate and combine effectively.
Innovation Solution
Development of novel compounds with both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity, allowing for a single molecule to provide bronchodilation through two independent modes of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate β2 adrenergic receptor agonist and muscarinic receptor antagonist compounds are used to treat pulmonary disorders, then therapeutic efficacy is achieved through dual modes of action, but formulation complexity and treatment burden increase
Solution Approach 1:
The patent combines two separate pharmacological functions (β2 adrenergic agonist and muscarinic antagonist activities) into a single molecular structure. The compound of formula I integrates both activities through specific structural features: a piperidine ring system with substituents that provide β2 agonist activity and a carbonyl group that provides muscarinic antagonist activity, eliminating the need for separate formulation of two different compounds
Solution Approach 2:
The invention creates a universal therapeutic agent that performs multiple functions simultaneously. The single compound structure is designed to interact with both β2 adrenergic receptors (providing bronchodilation) and muscarinic receptors (providing anticholinergic effects), making one molecule serve the dual therapeutic purposes previously requiring separate agents
2Reliability
If two separate compounds (β2 adrenergic agonist and muscarinic antagonist) are formulated together, then comprehensive therapeutic coverage is achieved, but ease of formulation and combination with other agents decreases
Solution Approach 1:
The patent merges two therapeutic functions into one molecular entity, simplifying the formulation process. Instead of formulating and co-administering two separate compounds, the invention provides a single compound of formula I that inherently possesses both β2 adrenergic agonist and muscarinic antagonist activities, reducing formulation complexity
Solution Approach 2:
The compound is designed as a universal agent that can be formulated with other therapeutic agents more easily. The single-molecule structure with integrated dual activity serves as a versatile platform for combination therapies, improving ease of formulation compared to coordinating multiple separate active ingredients
3Reliability
If separate bronchodilator compounds are administered, then targeted pharmacological effects are achieved, but treatment simplicity and patient compliance deteriorates
Solution Approach 1:
The invention merges two pharmacological actions (β2 agonism and muscarinic antagonism) into a single administered molecule. This eliminates the need for patients to manage multiple separate inhalers or medications, simplifying treatment while maintaining both pharmacological effects through the integrated compound structure
Data Source
AI summary
This invention provides compounds of formula I:wherein R1, R2, R3, R4,R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.